Mersana Therapeutics, Inc. MRSN
29.08 USD 0.00 (+0.00%)
At closeJan 6, 2026, 4:00 PM EST
29.36 +0.28 +0.96%
After hours · Jan 6, 4:00 PM ET
28.78 Day range 29.08
52-week range unavailable
- YTD
- +0.52%
- 1 year
- -14.47%
News
defenseworld.net Cwm LLC Cuts Stock Holdings in Mersana Therapeutics, Inc. $MRSN Cwm LLC lowered its position in shares of Mersana Therapeutics, Inc. (NASDAQ: MRSN) by 96.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
prnewswire.com Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN) BALA CYNWYD, Pa. , Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason…
prnewswire.com Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE , Dec. 16, 2025 /PRNewswire/ -- The Ademi Firm continues to investigate Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced…
prnewswire.com Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
globenewswire.com Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
prnewswire.com Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
globenewswire.com HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), who has…
businesswire.com Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
prnewswire.com Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
zacks.com Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.44. This compares to a loss of $2.25 per share a year ago.
benzinga.com Earnings Scheduled For November 14, 2025 
globenewswire.com $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. (NASDAQ: MRSN) NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders…
seekingalpha.com Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript Mersana Therapeutics, Inc. ( MRSN ) M&A Call November 13, 2025 8:00 AM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President &…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results 
prnewswire.com Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE , Nov. 13, 2025 /PRNewswire/ -- The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced…
benzinga.com Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout Day One Biopharmaceuticals (NASDAQ: DAWN) on Thursday agreed to acquire Mersana Therapeutics Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of…
benzinga.com Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results 
businesswire.com MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
globenewswire.com Day One Biopharmaceuticals to Acquire Mersana Therapeutics Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per…
globenewswire.com Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs)…
zacks.com Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is…
seekingalpha.com Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice…
benzinga.com Earnings Scheduled For August 13, 2025 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Earnings Scheduled For May 15, 2025 
benzinga.com Earnings Scheduled For March 3, 2025 
benzinga.com This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Earnings Scheduled For November 13, 2024 - benzinga.com Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
benzinga.com Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the…
benzinga.com Earnings Scheduled For November 7, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
benzinga.com Why Avantor Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023 - benzinga.com Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023
- benzinga.com Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
- benzinga.com Earnings Scheduled For May 9, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
- benzinga.com Earnings Scheduled For February 28, 2023 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
- benzinga.com Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
- benzinga.com Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday Gainers
- benzinga.com Earnings Scheduled For November 7, 2022 Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.